Cyproheptadine

DRUG13 trials

Sponsors

Brown University, St. Justine's Hospital, T. George Hornby, University of Michigan, Medical College of Wisconsin

Conditions

ADHDAlcohol Use DisorderAlcoholismAttention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity DisorderAttention Deficit and Disruptive Behavior DisordersAvoidant Restrictive Food Intake DisorderCOVID-19

Early Phase 1

Mechanisms of Neuromuscular Fatigue Post Stroke

CompletedNCT01688570

Medical College of WisconsinStroke

Start: 2011-08-31End: 2015-05-31Updated: 2015-11-05

Phase 2

A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking

CompletedNCT01076283

Brown UniversityAlcoholism

Start: 2009-12-31End: 2010-05-31Updated: 2013-10-17

A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain

TerminatedNCT01675050

University of MichiganFunctional Abdominal Pain

Start: 2012-08-31End: 2013-08-31Updated: 2017-08-30

Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

CompletedNCT04108104

Kinnov TherapeuticsAlcohol Use Disorder

Start: 2019-11-30End: 2022-01-31Updated: 2024-04-15

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active, not recruitingNCT04488081

QuantumLeap Healthcare CollaborativeCOVID-19

Start: 2020-07-31End: 2030-07-31Target: 1500Updated: 2026-03-16

Pediatric Oncology Nutrition Intervention Trial

CompletedNCT06175273

Corey HawesMalnutrition, Child, Muscle Loss, Nutrition Aspect of Cancer +2

Start: 2024-01-31End: 2025-08-04Updated: 2025-09-18

Phase 3

Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19

Hospital de Clinicas de Porto AlegreCOVID-19 Pneumonia

Start: 2021-07-26End: 2022-02-28Target: 274Updated: 2021-08-03

Phase 4

Cyproheptadine as an Appetite Stimulant

St. Justine's HospitalFailure to Thrive

Start: 2010-12-31End: 2012-01-31Target: 20Updated: 2011-03-15

A Study of Combination Therapy in Children With ADHD

CompletedNCT01940978

Douglas SearsADHD, Attention Deficit and Disruptive Behavior Disorders, Attention Deficit Disorder With Hyperactivity +2

Start: 2014-03-31End: 2015-03-31Updated: 2015-04-10

Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders

TerminatedNCT02568007

Medical College of WisconsinFeeding Behaviors

Start: 2015-12-31End: 2016-08-31Updated: 2020-01-31

The Use of Cyproheptadine in Pediatric Feeding Disorders

Active, not recruitingNCT06751290

University of MiamiAvoidant Restrictive Food Intake Disorder, Pediatric Feeding Disorder, Chronic

Start: 2024-12-30End: 2026-04-30Target: 50Updated: 2026-03-05

Unknown Phase

Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury

CompletedNCT01538693

T. George HornbySpinal Cord Injury

Start: 2011-12-31End: 2015-05-31Target: 30Updated: 2015-05-19

Altering Activation Patterns Post-stroke

CompletedNCT02418949

Shirley Ryan AbilityLabHemiparesis, Muscle Spasticity, Stroke

Start: 2015-11-01End: 2022-03-23Updated: 2026-03-31

Related Papers

Simulation-Based Bayesian Predictive Probability of Success for Interim Monitoring of Clinical Trials With Competing Event Data: Two Case Studies.

2026-01-011 citations

Systematic data capture reduces the need for source data verification: exploratory analysis from a phase 2 multicenter randomized controlled platform trial.

2025-10-29

Anti-CD14 Treatment in Patients With Severe COVID-19 Clinical and Biological Effects in a Phase 2 Randomized Open-Label Adaptive Platform Clinical Trial

CHEST Critical Care2024-12-092 citations

Phosphatidylethanol measures in patients with severe <scp>COVID</scp>‐19‐associated respiratory failure identify a subset with alcohol misuse

Alcohol Clinical and Experimental Research2024-11-26

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial.

2023-03-0318 citations

Use of cyproheptadine hydrochloride (HCl) to reduce neuromuscular hypertonicity in stroke survivors: A Randomized Trial: Reducing Hypertonicity in Stroke.

2022-08-305 citations

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations

BMJ Open2022-06-0125 citations

An innovative combination of cypropheptadine and prazosin for the treatment of alcohol use disorder: a double-blind, randomised, parallel-group, three-arm, multicentre, placebo-controlled phase 2 trial

European Psychiatry2022-06-01